Allosteric Antagonist Modulation of TRPV2 by Piperlongumine Impairs Glioblastoma Progression

João Conde(Universidade Nova de Lisboa), Gonçalo J. L. Bernardes(Instituto de Medicina Molecular João Lobo Antunes), Nuno L. Barbosa‐Morais(University of Lisbon), Ana Guerreiro(University of Lisbon), Tobias Weiß(University of Zurich), Michael Weller(University Hospital of Zurich), Sohyon Lee(ETH Zurich), Sandra H. Vaz(University of Lisbon), Ruth A. Pumroy(Translational Therapeutics (United States)), P. Filippakopoulos(Ludwig Cancer Research), Seungil Han(Pfizer (United States)), Marta C. Marques(University of Lisbon), Vera Y. Moiseenkova‐Bell(Translational Therapeutics (United States)), Tânia Carvalho(University of Lisbon), Berend Snijder(ETH Zurich), Marc Remke(Saarland University), Charlotte Baker(University of Lisbon), Rafael Roque(Hospital de Santa Maria), Amrita Samanta(Translational Therapeutics (United States)), Elvira P. Leites(University of Lisbon), Francisco Corzana(Universidad de La Rioja), Tiago Rodrigues(University of Lisbon), Daniel Picard(Heidelberg University), Bernardo P. de Almeida(Research Institute of Molecular Pathology), Vanessa A. Morais(University of Lisbon), Yuhang Liu(Changchun Institute of Applied Chemistry), Bárbara B. Sousa(University of Lisbon), Florian Sieglitz(University of Lisbon), Cláudia C. Faria(University of Lisbon), Maike Langini(Heidelberg University)
ACS Central Science
April 14, 2021
Cited by 63


Related Papers